Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9056+ simvastatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | simvastatin |
| Period 2 | EXPERIMENTAL | simvastatin + AZD9056 |
| Name | Type | Description |
|---|---|---|
| simvastatin | DRUG | One single dose of 40mg |
| AZD9056 + simvastatin | DRUG | AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7 |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Male or female healthy subjects. Females should not be of childbearing potential * Clinically normal physical and laboratory findings as judged by the investigator, including negative test results for drug...
AZD9056 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It has been evaluated in clinical trials involving patients with rheumatoid arthritis and in healthy volunteers for safety and drug interaction studies. The drug is not approved and remains in clinical development.
AZD9056 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored clinical trials of AZD9056 in rheumatoid arthritis and healthy volunteers.
AZD9056 has completed a Phase 2b clinical trial in patients with rheumatoid arthritis. It has also completed Phase 1 studies in healthy volunteers. The drug is investigational and has not received regulatory approval.
AZD9056 has been studied in two completed trials. NCT00520572 was a Phase 2b randomized, double-blind, placebo-controlled study in 385 patients with rheumatoid arthritis. NCT00700986 was a Phase 1 crossover study in 12 healthy male volunteers to investigate retinal function. NCT00736606 was a Phase 1 drug interaction study with simvastatin in healthy volunteers.
AZD9056 is the sole name used for this investigational drug in clinical trial records. No alternative names have been associated with it in the available trial information.